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ABSTRACT
Background and the purpose of the study: The combination of angiotensin II receptor antagonists 
and HMG CoA reductase inhibitors have shown to confer renoprotection.The purpose of this 
study was to find out the renoprotective effects of telmisartan and atorvastatin in combination 
and in monotherapy of  Streptozotocin (STZ)  induced diabetic nephropathy in rats. 
Methods: Diabetes was induced by i.p injection of STZ to rats, after 18 hrs of fasting. Diabetic 
rats were randomly grouped and treated with telmisartan and atorvastatin in combination as well 
as monotherapy for 30 days. The serum and urine glucose, creatinine and serum triglyceride, 
cholesterol, albumin and micro-albumin and blood urea nitrogen, total protein and histological 
analyses of the left kidney were performed at the end of the study. 
Results: By the end of the study, the combination showed significant (P < 0.05) improvement 
in urine glucose, serum cholesterol, serum and urine creatinine, blood urea nitrogen, total 
protein, serum albumin, micro-albuminuria levels in comparison to monotherapy. However, this 
combination didn’t show significant changes on serum glucose and triglyceride levels. Kidney 
pathological injury was attenuated by the combination as compared to the diabetic group.
Conclusion: The present study document that, telmisartan and atorvastatin combination have 
better renoprotective effects but not with individual drug when compared to the diabetic 
group. The combination also attenuated the progression of diabetic nephropathy by slowing 
the proteinuria and microalbuminuria and these effects were confirmed by  histopathological  
analysis.
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INTRODUCTION
Diabetic nephropathy is a major long-term 
complication of diabetes mellitus. Clinically there is 
development of microalbuminuria with progression 
to overt proteinuria, increased in blood pressure and 
reduced renal function (1). Excessive deposition 
of extracellular matrix protein in the glomeruli 
and subsequent mesangial expansion are the main 
structural alterations in diabetic nephropathy (2).
Accumulating evidences suggest that in patients 
with diabetes mellitus there is increased rates of 
lipoprotein oxidation. Hyperlipidemia may be 
involved in the pathogenesis of renal injury and is 
also considered a risk factor for diabetic nephropathy 
(3). Inhibition of HMG CoA reductase by statins not 
only reduces cholesterol synthesis, but also  decrease 
levels of geranylgeranyl phosphate and farnesyl 
pyrophosphate, which have important roles in the 
post translation modification of proteins (4).
Several large clinical trials have recently 
demonstrated that control of hypertension by 
angiotensin converting enzyme inhibitors and 
angiotensin  II  receptor  antagonists  significantly 
delayed the progression of diabetic nephropathy due 
to the reduction of blood pressure (5). Angiotensin 
II is known as a vasoactive substance which has 
also growth factor properties, being able to induce 
hypertrophy, proliferation and production of 
proteins of extracellular matrix in kidney cells and 
mimick the effect of high glucose concentration in 
diabetes (6). Treatment with angiotensin II receptor 
antagonist has shown to normalize urinary protein 
excretion and renal structural changes (7).
The aim of the present study was to assess the 
renoprotective effects of a combination of an 
angiotensin II receptor antagonist with an HMG 
CoA reductase inhibitor in experimental diabetes. 
MATERIAL AND METHODS
Chemicals
Atorvastatin was obtained as a gift sample from 
Shantam Pharma Pvt Ltd, Gandhinagar and 
Telmisartan was obtained as a gift sample from 
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purchased from Prolabs Marketing Pvt. Ltd., Delhi. 
Analytical grades, citric acid, tri sodium citrate, 
sodium dihydrogen orthophosphate, disodium 
hydrogen phosphate and formaldehyde procured 
from Merck laboratories, and Nice chemicals.
Animals
All the experiments were carried out with male 
albino wistar rats, 150-250g (Indian Institue of 
Sciences, Bangalore, Karnataka). Rats were housed 
in polyacrylic cages (38×23×10 cm) at maximum 
four animals per cage. They were housed in an 
air conditioned room and were kept in standard 
laboratory conditions under natural light  dark cycle 
(approximately 14 h light/ 10 h dark)  maintained 
humidity 60±5%  and an ambient temperature of 
25±2˚C.  All animals had free access to standard 
diet (Amrut rat feed, Bangalore) and tap water 
ad libitumand and allowed to acclimatize for one 
week before the experiments. Commercial pellet 
diet contained 22 % protein, 4% fat, 4% fiber, 36% 
carbohydrates and 10% ash (w/w). The experiment 
was carried out according to the guidelines of the 
Committee for the Purpose of Control Supervision 
of Experiments on Animals (CPCSEA), New Delhi, 
India. approved by the institutional animal ethical 
committee of Acharya and B. M. Reddy College 
of Pharmacy, Bangalore (Approval No.  IAEC /
Ph.cology/06/2009-10).
Experimentation
After 18 hrs fasting male wistar albino rats (150-250 
gm) diabetes were induced by i.p injection of a single 
dose of STZ (45 mg/kg). STZ was dissolved in cold 
citrate buffer (pH 4.5) immediately before use and 
solution were made fresh daily. 
Following the induction of diabetes animals were 
randomly allocated into 5 groups with 6 rats per group; 
(1) control rats, (2) diabetic rats with no treatment, (3) 
diabetic rats treated with atorvastatin (10 mg/kg, p.o.), 
(4) diabetic rats treated with telmisartan, (10 mg/kg, 
p.o.), (5) diabetic rats treated with the combination of 
both atorvastatin, (10 mg/kg, p.o.) and telmisartan (10 
mg/kg, p.o.) and were treated for 30 days. 
The blood was drawn from the retro orbital plexus 
of the diabetic wistar albino rats; under light 
ether anesthesia on the respective days and the 
serum glucose, creatinine the blood urea nitrogen, 
cholesterol, triglycerides and albumin were measured. 
Animals were accommodated in metabolic cages for 
urine collection for 2 days in order to become familiar 
Table 1. Serum glucose, cholesterol, triglyceride, albumin, creatinine and blood urea nitrogen levels in rats following treatment with 
atorvastatin, telmisartan and the combinations.
 .Pa< 0.05 (s) compared to diabetic group
 .Pa< 0.05 (s) compared to diabetic group
Groups
Serum glucose
(mg/dl)
Serum cholesterol
(gm/dl)
Serum triglyceride
(mg/dl)
Blood urea nitrogen
(mg/dl)
Serum albumin
(mg/dl)
Serum creatinine
(mg/dl)
Control 89.28±4.611 51.57±6.928 117.30±10.11 19.38±1.471 3.281±0.156 0.612±0.0612
Diabetic 423.41±21.05 106.48±5.812 181.35±8.046 53.2±3.392 2.353±0.158  1.078±0.0593
bD + 
Atorvastatin
415.19±16.08 ns 79.02±4.840 ns 157.49±12.00 ns 33.64±1.840a 2.807±0.238ns 0.98±0.0296 ns
D + Telmisartan 409.42±22.75 ns 100.02±1.871ns 162.14±5.386 ns 37.17±2.003a 2.976±0.086 ns 0.957±0.0796 ns
D + Atorvastain 
+ Telmisartan
413.99±34.93 ns 77.89±8.746 a 147.27±10.52 ns 31.92±1.784a 3.012±0.248 a 0.933±0.0849a
Groups
Urine glucose
(mg/dl)
Microalbuminuria
(mg/dl)
Urine creatinine
(mg/dl)
Total protein
(mg/dl)
Histopathology
(Score)
Control 13.09±3.701 6.75±0.8447 58.76±1.096 54.68±5.337 0.65
Diabetic 988.09±13.37 13.94±0.3922 15.94±0.5970 138.01±7.970 3
D + Atorvastatin 375±18.71a 9.38±0.5730a 23.51±0.8325 a 107.25±11.20 ns 2.33a
D + Telmisartan 371.79±12.73a 9.33±0.2842a 28.97±1.233a 117.20±4.060 ns 2.5 a
D + Atorvastain + 
Telmisartan
368.12±20.69 a 8.73±0.1763a 34.19±1.168a 95.62±9.407a 1.75 a
 Table 2. Urine glucose, microalbuminuria, creatinine and total protein in rats after treatment with atorvastatin, telmisartan and their
combinations
B,D: Diabetic 
B,D: Diabetic 
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with the environment of the cage. On the, second day, 
24 hrs urine samples were collected from all groups 
to determine urine glucose, creatinine, albumin and 
total protein. Urine was centrifuged and kidneys 
were  removed  and  fixed  in  formalin  solution  for 
histological studies.
Statistical Analyses
All measurements which were performed were 
blinded by the same operator. Data presented mean 
+ SEM. The treated groups were compared with the 
respective diabetic groups using ANOVA followed by 
Dunnett multi comparison test using Graphad Instat. 
P < 0.05 considered as significant.
RESULTS
The results of the combination treatment showed 
significant (P < 0.05) changes in serum cholesterol, 
creatinine, albumin and blood urea nitrogen levels 
in comparison with diabetic group, but not with 
individual drug. However, this combination did not 
show any effect on serum glucose and triglyceride 
levels when compared with diabetic group.
The combination also showed significant (P < 0.05) 
changes in urine glucose, creatinine, microalbuminuria 
and total protein levels in comparison with diabetic 
group.
There was a minimal improvement in atorvastatin 
and telmisartan groups when compared to diabetic 
group. There was a slight improvement in atorvastatin 
group in comparison to telmisartan group.
DISCUSSION
The present study demonstrated that combination 
of an angiotensin II receptor antagonist and 
an HMG-CoA reductase inhibitor attenuated 
the increase in albuminuria in the kidney of 
experimental diabetes. The combination of 
atorvastatin  and  telmisartan  showed  significant 
(P<0.05) reduction in albuminuria. Angiotensin 
converting enzyme inhibitors or angiotensin II 
receptor antagonist have potent antiproteinuric and 
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